The mobile devices caused a constant struggle for the pursuit of data privacy. Nowadays, it appears that the number of mobile devices in the world is increasing. With this increase and technological evolution, thousands of data associated with everyone are generated and stored remotely. Thus, the topic of data privacy is highlighted in several areas. There is a need for control and management of data in circulation inherent to this theme. This article presents an approach of the interaction between the individual and the public environment, where this interaction will determine the access to information. This analysis was based on a data privacy management model in public environments created after reading and analyzing the current technologies. A mobile application based on location via Global Positioning System (GPS) was created to substantiate this model, which it considers the General Data Protection Regulation (GDPR) to control and manage access to the data of each individual.

The COVID-19 pandemic plagues the whole world, bringing numerous challenges which need to be addressed. One of them is the privacy of patient data. There are several problems related to data privacy in IoT environments, the use of applications, devices, and functionalities in hospital processes. Therefore, we have compared works from the literature and developed a taxonomy consisting of the requirements necessary to control patient privacy data in a hospital setting in the current pandemic. Based on the studies, an application was modeled and implemented. According to the tests and comparisons drawn between the variables, the application yielded satisfactory results.

During the last decades West Nile Virus (WNV) outbreaks have continuously occurred in the Mediterranean area. In August 2020 a new WNV outbreak affected 71 people with meningoencephalitis in Andalusia and 6 more cases in Extremadura (south-west of Spain), causing a total of eight deaths. The whole genomes of four viral isolates were obtained and phylogenetically analyzed in the context of recent outbreaks. The Andalusian viral samples belonged to the lineage 1 and were relatively similar to previous outbreaks occurred in the Mediterranean region. Here we present a detailed analysis of the outbreak, including an extensive phylogenetic study.

Background: Although no specific treatment for COVID 19 has been proven effective yet, some drugs with in vitro potential against SARS-CoV-2 virus have been proposed for clinical use. Hydroxychloroquine has in vitro anti-viral and immunomodulatory activity, but there is no current clinical evidence of its effectiveness on the outcome of the disease. Methods: We enrolled all 18-85 years old inpatients from Central Defense Hospital, Madrid, Spain, who were hospitalised due to COVID-19 and had a definitive outcome (either dead or discharged). We used a statistical survival analysis. Results: We analysed 220 medical records. 166 patients met the inclusion criteria. 48,8 % of patients not treated with HCQ died, versus 22% in the group of hydroxychloroquine (p=0,002). According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1,4 to 1,8 times. This difference was statistically significant in the mild group. Conclusions: in a cohort of 166 patients between 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with an initial loading dose of 800mg improved patient survival when admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will need to be clarified in subsequent studies.